HIV drug development: the next 25 years.
The development of drugs for HIV infection began soon after the virus was discovered 25 years ago. Since then, progress has been substantial, but numerous uncertainties persist about the best way to manage this disease. Here we review the current treatment options, consider novel mechanisms that can be exploited for existing drug targets, and explore the potential of novel targets. With a view to the next quarter century, we consider whether drug resistance can be avoided, which drug classes will be favoured over others, which strategies are most likely to succeed, and the potential impact of pharmacogenomics and individualized therapy.
Flexner
Charles
C
Johns Hopkins University, Divisions of Clinical Pharmacology and Infectious Diseases, Departments of Medicine, Pharmacology and Molecular Sciences, and International Health, Baltimore, Maryland 21287-5554, USA. flex@jhmi.edu
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D015507:Drugs, Investigational; D006801:Humans; D004364:Pharmaceutical Preparations
D019380:Anti-HIV Agents; D015507:Drugs, Investigational; D004364:Pharmaceutical Preparations